Stay updated on Pembrolizumab & Lanreotide for GI NETs Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.

Latest updates to the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page
- Check4 days agoChange DetectedAdded a Locations section listing North Carolina (Duke University Medical Center, Durham) and South Carolina (Columbia and Lexington Medical Center) study sites, replacing the prior separate state location headings; removed the HHS Vulnerability Disclosure link in the footer as part of Revision: v3.3.3.SummaryDifference0.3%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe page footer revision label was updated from v3.2.0 to v3.3.2, indicating a minor update to the page metadata. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange DetectedRemoval of the government funding notice banner at the top of the ClinicalTrials.gov study page.SummaryDifference0.4%

- Check54 days agoChange DetectedNo substantive changes to the study details or eligibility criteria are evident between the two screenshots; any differences seem to be formatting, spacing, or UI elements rather than content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check83 days agoChange DetectedMajor update: adds current operating status notice and links for NIH Clinical Center, and bumps version to v3.2.0, replacing the old v3.1.0.SummaryDifference3%

- Check90 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab & Lanreotide for GI NETs Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.